Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2525)	11/2/2009 10:33:13 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

HGSI opened with another UG and is up 35.15% with volume now > 15,320,300 which is already > 2x its ADV.<g> bigcharts.marketwatch.com It announced today, together with GSK,that BENLYSTA met the primary endpoint in BLISS-76, the second of two PIIIs in seropositive patients with SLE. Results through 52 wks. showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response as measured by the SLE Responder Index, compared with placebo plus standard of care. The drug was generally well tolerated,with a similar rate of discontinuations due to adverse events. HGSI's CEO said that the results confirm their view that the drug has the potential to become the first new approved drug in decades for SLE. BENLYSTA is being developed by HGS and GSK under a co-development agreement entered into in Aug 2006. The ACTAY is $24.50 and the stock is already trading above that and its Aug 26 H bigcharts.marketwatch.com Bernard